Latest Insider Transactions at Incyte Corp (INCY)
This section provides a real-time view of insider transactions for Incyte Corp (INCY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of INCYTE CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of INCYTE CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 02
2021
|
Yao Wenqing EVP, Head of Discovery Chem |
SELL
Payment of exercise price or tax liability
|
Direct |
2,953
-2.9%
|
$245,099
$83.58 P/Share
|
|
Jul 02
2021
|
Yao Wenqing EVP, Head of Discovery Chem |
BUY
Grant, award, or other acquisition
|
Direct |
7,853
+7.15%
|
-
|
|
Jul 02
2021
|
Paul Trower Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
872
-2.62%
|
$72,376
$83.58 P/Share
|
|
Jul 02
2021
|
Paul Trower Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,521
+11.97%
|
-
|
|
Jul 01
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
396
-1.49%
|
$33,264
$84.09 P/Share
|
|
Jun 30
2021
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
283
+3.73%
|
$23,772
$84.13 P/Share
|
|
Jun 30
2021
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
238
+3.01%
|
$19,992
$84.13 P/Share
|
|
Jun 30
2021
|
Wendy L Dixon Director |
BUY
Grant, award, or other acquisition
|
Direct |
214
+1.24%
|
$17,976
$84.13 P/Share
|
|
Jun 30
2021
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
208
+4.12%
|
$17,472
$84.13 P/Share
|
|
Jun 30
2021
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
690
+0.01%
|
-
|
|
Jun 29
2021
|
Yao Wenqing EVP, Head of Discovery Chem |
SELL
Open market or private sale
|
Direct |
27,194
-22.42%
|
$2,311,490
$85.37 P/Share
|
|
Jun 28
2021
|
Yao Wenqing EVP, Head of Discovery Chem |
SELL
Payment of exercise price or tax liability
|
Direct |
22,806
-15.83%
|
$1,938,510
$85.61 P/Share
|
|
Jun 28
2021
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,079
-18.44%
|
$1,876,715
$85.61 P/Share
|
|
Jun 18
2021
|
Maria E Pasquale EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
255
+0.84%
|
$16,575
$65.36 P/Share
|
|
Jun 10
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,845
-12.65%
|
$334,515
$87.0 P/Share
|
|
Jun 10
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,845
+11.23%
|
$249,925
$65.42 P/Share
|
|
Jun 01
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
395
-1.47%
|
$33,180
$84.13 P/Share
|
|
May 26
2021
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,923
+15.06%
|
-
|
|
May 26
2021
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,923
+21.51%
|
-
|
|
May 26
2021
|
Wendy L Dixon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,923
+10.27%
|
-
|
|
May 26
2021
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,923
+20.55%
|
-
|
|
May 26
2021
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,923
+29.33%
|
-
|
|
May 26
2021
|
Katherine A High Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,923
+36.51%
|
-
|
|
May 26
2021
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
3,846
+0.04%
|
-
|
|
May 14
2021
|
Baker Bros. Advisors LP |
BUY
Exercise of conversion of derivative security
|
Indirect |
40,000
+0.38%
|
$720,000
$18.97 P/Share
|
|
May 03
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
396
-1.45%
|
$33,660
$85.4 P/Share
|
|
Apr 23
2021
|
Maria E Pasquale EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
127
+0.42%
|
$8,255
$65.36 P/Share
|
|
Apr 09
2021
|
Maria E Pasquale EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
517
-1.7%
|
$40,843
$79.96 P/Share
|
|
Apr 01
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
396
-1.43%
|
$32,076
$81.57 P/Share
|
|
Mar 31
2021
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
298
+5.53%
|
$24,138
$81.27 P/Share
|
|
Mar 31
2021
|
Wendy L Dixon Director |
BUY
Grant, award, or other acquisition
|
Direct |
225
+1.49%
|
$18,225
$81.27 P/Share
|
|
Mar 31
2021
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
219
+7.47%
|
$17,739
$81.27 P/Share
|
|
Mar 31
2021
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
251
+4.36%
|
$20,331
$81.27 P/Share
|
|
Mar 31
2021
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
728
+0.01%
|
-
|
|
Mar 29
2021
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Open market or private sale
|
Direct |
20,000
-30.56%
|
$1,620,000
$81.08 P/Share
|
|
Mar 12
2021
|
Maria E Pasquale EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
128
+0.42%
|
$8,320
$65.36 P/Share
|
|
Mar 01
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
395
-1.4%
|
$31,205
$79.73 P/Share
|
|
Feb 23
2021
|
Herve Hoppenot Chairman / CEO |
BUY
Open market or private purchase
|
Direct |
12,925
+4.35%
|
$995,225
$77.37 P/Share
|
|
Feb 16
2021
|
Maria E Pasquale EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
127
+0.42%
|
$8,255
$65.36 P/Share
|
|
Feb 11
2021
|
Christiana Stamoulis EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,210
-3.58%
|
$101,640
$84.99 P/Share
|
|
Feb 01
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,356
-2.32%
|
$122,040
$90.0 P/Share
|
|
Feb 01
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
961
+3.16%
|
$62,465
$65.42 P/Share
|
|
Jan 25
2021
|
Jonathan Elliott Dickinson EVP, General Manager, Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
78
-0.29%
|
$7,800
$100.5 P/Share
|
|
Jan 25
2021
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
78
-0.12%
|
$7,800
$100.5 P/Share
|
|
Jan 25
2021
|
Barry P Flannelly EVP & General Manager US |
SELL
Open market or private sale
|
Direct |
2,744
-5.2%
|
$274,400
$100.0 P/Share
|
|
Jan 25
2021
|
Vijay K Iyengar EVP, GMAPPS |
SELL
Open market or private sale
|
Direct |
5,116
-8.42%
|
$506,484
$99.0 P/Share
|
|
Jan 25
2021
|
Vijay K Iyengar EVP, GMAPPS |
BUY
Exercise of conversion of derivative security
|
Direct |
4,116
+11.63%
|
$296,352
$72.86 P/Share
|
|
Jan 25
2021
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,795
-3.07%
|
$379,500
$100.0 P/Share
|
|
Jan 25
2021
|
Steven H Stein EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,795
+2.98%
|
$258,060
$68.62 P/Share
|
|
Jan 25
2021
|
Yao Wenqing EVP, Head of Discovery Chem |
SELL
Open market or private sale
|
Direct |
21,545
-6.64%
|
$2,154,500
$100.0 P/Share
|